Article
An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.
Journal of controlled release : official journal of the Controlled Release Society - 10 Jan 2026
Park Seong Jin, Cho Young Seok, Lee Jae-Hyeon, Kim Sang Yoon, Byun Youngro, Park Jooho, Kim Ha Rin
Abstract excerpt
Kirsten rat sarcoma virus (KRAS)-mutant colorectal cancer remains a major clinical challenge due to its resistance to conventional therapies and an immunosuppressive tumor microenvironment (TME) that limits immunotherapy efficacy. To overcome these barriers, we have engineered MPD1, designed to execute a precise, multi-stage attack. MPD1 features a dual-action mechanism: an albumin-binding moiety hijacks the...
Topics
- Animals
- Immunotherapy
- Tumor Microenvironment
- Proto-Oncogene Proteins p21(ras)
- Humans
- Cell Line, Tumor
- Mice
- Colorectal Neoplasms
- Mice, Inbred C57BL
- Female
- Drug Delivery Systems
- Mutation
- Pyrazoles